ULIPRISTAL ACETATE FOR UTERINE FIBROID-RELATED SYMPTOMS

被引：4

作者：

Puchar, A. ^{[1
]}

Luton, D. ^{[1
]}

Koskas, M. ^{[1
]}

机构：

[1] Paris Diderot Univ, Obstet & Gynecol, Bichat Univ Hosp, Paris, France

来源：

DRUGS OF TODAY | 2015年 / 51卷 / 11期

关键词：

Ulipristal acetate; Uterine fibroids; Uterine tumors; progesterone receptor modulators; PROGESTERONE-RECEPTOR MODULATOR; WOMEN; PLACEBO; PHARMACOKINETICS; LEIOMYOMATA; ASOPRISNIL; MANAGEMENT; EFFICACY; MYOMAS; IMPACT;

D O I：

10.1358/dot.2015.51.11.2413469

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Uterine fibroids are the most common benign uterine tumors in women of reproductive age. Although most women are asymptomatic (80%), fibroids, according to their type and location, can cause several symptoms and impact quality of life. To date, no medical treatment is able to eliminate fibroids. Ulipristal acetate (UPA) is an orally active synthetic selective progesterone receptor modulator (SPRM) characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis. It was licensed in Europe for preoperative fibroid treatment in 2012. Its pharmacological and pharmacodynamic characteristics, its efficacy and good tolerance make UPA a new important tool in the management of uterine fibroids.

引用

页码：661 / 667

页数：7

共 37 条

[1] Growth factors and cytokines in uterine leiomyomas
Andersen, J
[J]. SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY, 1996, 14 (03): : 269 - 282
[2] Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
Biglia, Nicoletta
Carinelli, Silvestro
Maiorana, Antonio
D'Alonzo, Marta
Lo Monte, Giuseppe
Marci, Roberto
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 285 - 292
[3] Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study
Bizzarri, Nicolo
Ghirardi, Valentina
Remorgida, Valentino
Venturini, Pier Luigi
Ferrero, Simone
[J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 192 : 22 - 26
[4] Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
Bourdet, Alice Trefoux
Luton, Dominique
Koskas, Martin
[J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 321 - 330
[5] Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
Chabbert-Buffet, N
Meduri, G
Bouchard, P
Spitz, IM
[J]. HUMAN REPRODUCTION UPDATE, 2005, 11 (03) : 293 - 307
[6] Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial
Chabbert-Buffet, Nathalie
Pintiaux-Kairis, Axelle
Bouchard, Philippe
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) : 3582 - 3589
[7] Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis
Chwalisz, K
Perez, MC
DeManno, D
Winkel, C
Schubert, G
Elger, W
[J]. ENDOCRINE REVIEWS, 2005, 26 (03) : 423 - 438
[8] The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women
Chwalisz, K
Elger, W
Stickler, T
Mattia-Goldberg, C
Larsen, L
[J]. HUMAN REPRODUCTION, 2005, 20 (04) : 1090 - 1099
[9] A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata
Chwalisz, Kristof
Larsen, Lois
Mattia-Goldberg, Cynthia
Edmonds, Anthony
Elger, Walter
Winkel, Craig A.
[J]. FERTILITY AND STERILITY, 2007, 87 (06) : 1399 - 1412
[10] Ulipristal acetate does not impact human normal breast tissue
Communal, Laudine
Vilasco, Myriam
Hugon-Rodin, Justine
Courtin, Aurelie
Mourra, Najat
Lahlou, Najiba
Dumont, Sylvie
Chaouat, Marc
Forgez, Patricia
Gompel, Anne
[J]. HUMAN REPRODUCTION, 2012, 27 (09) : 2785 - 2798

← 1 2 3 4 →